1. Home
  2. TOVX vs ADXN Comparison

TOVX vs ADXN Comparison

Compare TOVX & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theriva Biologics Inc.

TOVX

Theriva Biologics Inc.

HOLD

Current Price

$0.24

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Logo Addex Therapeutics Ltd

ADXN

Addex Therapeutics Ltd

N/A

Current Price

$3.38

Market Cap

8.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TOVX
ADXN
Founded
2001
2002
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
8.6M
IPO Year
2012
2019

Fundamental Metrics

Financial Performance
Metric
TOVX
ADXN
Price
$0.24
$3.38
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$1.00
N/A
AVG Volume (30 Days)
425.7K
96.0K
Earning Date
05-13-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
89.07
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$86.57
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$3.10
52 Week High
$0.86
$11.97

Technical Indicators

Market Signals
Indicator
TOVX
ADXN
Relative Strength Index (RSI) 47.77 33.77
Support Level $0.22 N/A
Resistance Level $0.26 $7.37
Average True Range (ATR) 0.01 0.28
MACD -0.00 0.04
Stochastic Oscillator 39.25 31.01

Price Performance

Historical Comparison
TOVX
ADXN

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

About ADXN Addex Therapeutics Ltd

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.

Share on Social Networks: